Last reviewed · How we verify

Rocuronium dosing — Competitive Intelligence Brief

Rocuronium dosing (Rocuronium dosing) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Neuromuscular blocking agent (non-depolarizing). Area: Anesthesia.

marketed Neuromuscular blocking agent (non-depolarizing) Nicotinic acetylcholine receptor at the neuromuscular junction Anesthesia Small molecule Live · refreshed every 30 min

Target snapshot

Rocuronium dosing (Rocuronium dosing) — Clare Hayes-Bradley. Rocuronium is a neuromuscular blocking agent that competitively binds to acetylcholine receptors at the neuromuscular junction, preventing muscle contraction.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
Rocuronium dosing TARGET Rocuronium dosing Clare Hayes-Bradley marketed Neuromuscular blocking agent (non-depolarizing) Nicotinic acetylcholine receptor at the neuromuscular junction
Vecuronium + Atracurium Vecuronium + Atracurium Sir Ganga Ram Hospital marketed Neuromuscular blocking agent (non-depolarizing) Nicotinic acetylcholine receptor at the neuromuscular junction
Deep neuromuscular block Deep neuromuscular block University of Medicine and Pharmacy at Ho Chi Minh City marketed Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium or Vecuronium Rocuronium or Vecuronium Merck Sharp & Dohme LLC marketed Neuromuscular blocking agent (non-depolarizing) Nicotinic acetylcholine receptor at the neuromuscular junction
NMBA - cisatracurium NMBA - cisatracurium CHU de Reims marketed Non-depolarizing neuromuscular blocking agent (NMBA) Nicotinic acetylcholine receptor at the neuromuscular junction
Rocuronium + sugammadex Rocuronium + sugammadex Brno University Hospital marketed Neuromuscular blocking agent (rocuronium) + selective relaxant binding agent (sugammadex) Nicotinic acetylcholine receptor at the neuromuscular junction (rocuronium); rocuronium molecule itself (sugammadex)
Neuromuscular Blocking Agents Neuromuscular Blocking Agents Fondazione Policlinico Universitario Agostino Gemelli IRCCS marketed Neuromuscular blocking agent Nicotinic acetylcholine receptor at the neuromuscular junction

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Neuromuscular blocking agent (non-depolarizing) class)

  1. Clare Hayes-Bradley · 1 drug in this class
  2. Diskapi Yildirim Beyazit Education and Research Hospital · 1 drug in this class
  3. Merck Sharp & Dohme LLC · 1 drug in this class
  4. Sir Ganga Ram Hospital · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Rocuronium dosing — Competitive Intelligence Brief. https://druglandscape.com/ci/rocuronium-dosing. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: